Igor Andrašina

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

Medicine, Oncology, Pharmacology +14

Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC

David Planchard, Pasi A. Jänne, Ying Cheng et al. · New England Journal of Medicine · 2023 · 650 citations · Full text

Medicine, Oncology, Pharmacology +7

Proteomic analysis of the vitamin C effect on the doxorubicin cytotoxicity in the MCF-7 breast cancer cell line

Peter Bober, Michal Alexovič, Ivan Talian et al. · Journal of Cancer Research and Clinical Oncology · 2016 · 25 citations · Full text

Medicine, Oncology, Pharmacology +13

Differential Urinary Proteomic Analysis of Endometrial Cancer

Mária Kacírová, Peter Bober, Michal Alexovič et al. · Physiological Research · 2019 · 13 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial

Milada Zemanová, Markéta Černovská, Libor Havel et al. · Cancer Treatment and Research Communications · 2021 · 13 citations · Full text

Medicine, Immunology, Oncology +15